Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PDX-PC

Financiado

Cerrado

Elucidation of tumour cell plasticity mechanisms associated to treatment in meta...

Elucidation of tumour cell plasticity mechanisms associated to treatment in metastatic prostate cancer Prostate cancer (PC) is among the top five leading malignancies causing cancer mortality worldwide. Increased prevalence and declined mortality rate have led to an increment in follow-ups with a significant rise in the economic bu... ver más

15/09/2021

FUNDACIO CLINIC PE...

166K€

Presupuesto del proyecto: 166K€

Líder del proyecto

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 650K€

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-09-15

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

FUNDACIO CLINIC PER A LA REC...

166.20K€ | Lider

MONASH UNIVERSITY

85.74K€ | Participante

Proyectos interesantes

TransPot

Medical Technol...

Data Science

3M€ Cerrado

RESICT-PC

Medical Technol...

Data Science

231K€ Cerrado

STOPCa

Medical Technol...

Data Science

175K€ Cerrado

SAF2014-55944-R

Medical Technol...

Data Science

145K€ Cerrado

PROSTarget

Medical Technol...

Data Science

165K€ Cerrado

STEM-BCPC

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 29 meses Fecha Inicio: 2019-04-02
Fecha Fin: 2021-09-15

Líder del proyecto

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 650K€

Presupuesto del proyecto 166K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Prostate cancer (PC) is among the top five leading malignancies causing cancer mortality worldwide. Increased prevalence and declined mortality rate have led to an increment in follow-ups with a significant rise in the economic burden. In the last few years, several new options for metastatic disease have been approved leading to clinicians to have multiple choices of therapy sequences. However, not all patients initially respond and most of them eventually develop resistance. The ability of tumour cells to reprogram themselves and survive despite the blocked targets (tumour cell plasticity) may accounts for the absence of durable responses. In addition, the fact that initial treatments may affect the potential benefit of subsequent treatments highlights the need to discover predictive biomarkers for optimal treatment selection, allowing early changes in treatment for non-responding patients. This multidisciplinary project aims to elucidate the molecular mechanisms responsible for tumour cell plasticity associated to treatment response in metastatic PC. Patient-derived xenografts (PDX) in vivo models will be used, since they preserve molecular heterogeneity and therapeutic response observed in the clinic. They will be treated under different regimens. Tumour tissues will be analysed by RNA sequencing before and after treatment. Bioinformatics analysis will be used to establish molecular signatures of treatment response that will be validated in liquid biopsy (circulating tumour cells and cell free DNA) from metastatic PC patients undergoing different treatments. PDX-PC will provide a better understanding of the molecular evolution of the disease that will contribute to design more specific and individualized treatments. In the setting of non-curative therapy, the implementation of such molecular findings at clinical practice may help to guide treatment decisions, improve outcomes, and prevent unnecessary side effects and costly therapies in men with metastatic PC.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores